Evidence map›Paper›PMID 34424905›Full record

ArticlePLoS neglected tropical diseases2021

Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel.

Amanda Ribeiro Dos Santos, Aline Dionizio, Mileni da Silva Fernandes, Marília Afonso Rabelo Buzalaf, Beatriz Pereira, Débora de Fátima Almeida Donanzam, Sergio Marrone Ribeiro, Anamaria Mello Miranda Paniago, Ricardo de Souza Cavalcante, Rinaldo Poncio Mendes and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Amanda Ribeiro Dos SantosFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil.ORCID 0000-0002-5577-4498
Aline DionizioFaculdade de Odontologia de Bauru (FOB), Universidade de São Paulo (USP), Bauru, Brazil.
Mileni da Silva FernandesFaculdade de Odontologia de Bauru (FOB), Universidade de São Paulo (USP), Bauru, Brazil.ORCID 0000-0002-6125-6697
Marília Afonso Rabelo BuzalafFaculdade de Odontologia de Bauru (FOB), Universidade de São Paulo (USP), Bauru, Brazil.ORCID 0000-0002-5985-3951
Beatriz PereiraFaculdade de Medicina, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.ORCID 0000-0001-5446-2671
Débora de Fátima Almeida DonanzamFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil.ORCID 0000-0002-7570-6337
Sergio Marrone RibeiroFaculdade de Medicina, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.ORCID 0000-0003-0732-2814
Anamaria Mello Miranda PaniagoFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil.ORCID 0000-0002-8925-7712
Ricardo de Souza CavalcanteFaculdade de Medicina, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.
Rinaldo Poncio MendesFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil.ORCID 0000-0002-0661-5917
James VenturiniFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil.ORCID 0000-0003-0035-2439
Universidade Federal de Mato Grosso do Sul · BRUniversidade de São Paulo · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary sequelae (PS) in patients with chronic paracoccidioidomycosis (PCM) typically include pulmonary fibrosis and emphysema. Knowledge of the molecular pathways involved in PS of PCM is required for treatment and biomarker identification. METHODOLOGY/PRINCIPAL

findingsThis non-concurrent cohort study included 29 patients with pulmonary PCM that were followed before and after treatment. From this group, 17 patients evolved to mild/ moderate PS and 12 evolved severe PS. Sera from patients were evaluated before treatment and at clinical cure, serological cure, and apparent cure. A nanoACQUITY UPLC-Xevo QT MS system and PLGS software were used to identify serum differentially expressed proteins, data are available via ProteomeXchange with identifier PXD026906. Serum differentially expressed proteins were then categorized using Cytoscape software and the Reactome pathway database. Seventy-two differentially expressed serum proteins were identified in patients with severe PS compared with patients with mild/moderate PS. Most proteins altered in severe PS were involved in wound healing, inflammatory response, and oxygen transport pathways. Before treatment and at clinical cure, signaling proteins participating in wound healing, complement cascade, cholesterol transport and retinoid metabolism pathways were downregulated in patients with severe PS, whereas signaling proteins in gluconeogenesis and gas exchange pathways were upregulated. At serological cure, the pattern of protein expression reversed. At apparent cure pathways related with tissue repair (fibrosis) became downregulated, and pathway related oxygen transport became upregulated. Additionally, we identified 15 proteins as candidate biomarkers for severe PS. CONCLUSIONS/SIGNIFICANCE: Development of severe PS is related to increased expression of proteins involved in glycolytic pathway and oxygen exchange), indicative of the greater cellular activity and replication associated with early dysregulation of wound healing and aberrant tissue repair. Our findings provide new targets to study mechanisms of PS in PCM, as well as potential biomarkers.

Indexed as

AdultAgedBiomarkersChromatography, High Pressure LiquidCohort StudiesFemaleHumansMaleMass SpectrometryMiddle AgedParacoccidioidesParacoccidioidomycosisProteomicsSerumBiomarkers

Identifiers

PMID34424905
PMCPMC8425554
OpenAlexW3194225513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.